MMGPE: Beyond Conventional AI Drug Discovery (Target-Centric AI)

Artificial intelligence has transformed early-stage drug discovery by accelerating target identification, protein structure prediction, molecular design, and virtual screening. Representative platforms such as Isomorphic Labs, Insilico Medicine, Recursion, and Generate Biomedicines have demonstrated the potential of AI to accelerate therapeutic discovery through target-centric and molecular-level approaches. Many complex diseases, however, are driven by multiple interacting biological pathways rather than a single dominant molecular target. Patients sharing the same diagnosis frequently exhibit markedly different underlying biology, contributing to heterogeneous therapeutic responses and late-stage clinical trial failure. The Multi-Mechanism Guidance and Personalization Platform (MMGPE) provides a complementary systems-level framework. Rather than beginning with molecular targets, MMGPE models diseases as interacting biological pathways, evaluates therapeutic coverage, identifies residual mechanistic gaps, and supports pathway-guided therapeutic prioritization, precision clinical trial enrollment, companion diagnostics, and translational decision support.